戻る
Cardiff Oncology Inc (CRDF)価格
CRDF 株価推移チャート
CRDF 収入
Cardiff Oncology Inc
$2
-31.97%
$-0.94
終値： Jan 27, 16:00:00 GMT-5
$2.01
0.49%
$0
アフターマーケット：Jan 27, 18:19:39 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-06
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
CRDFの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Cardiff Oncology Inc CRDFの前四半期の収益はどうでしたか？
Cardiff Oncology Incの収益見積もりはいくらですか？
Cardiff Oncology Incの収益品質スコアはどれくらいですか？
Cardiff Oncology Incはいつ収益を報告しますか？
Cardiff Oncology Incの予想収益はいくらですか？
Cardiff Oncology Incは収益予想を上回りましたか？
主要データ
前終値
$2.94
始値
$2.06
当日レンジ
$1.85 - $2.1
52週レンジ
$1.9 - $4.99
取引高
11.1M
平均取引高
878.6K
1株当たり利益(TTM)
-0.80
配当利回り
--
時価総額
$135.3M
CRDFとは何ですか？
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2004-07-27. The company is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. The company is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The company has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.